PD-L1 APP
Non-small cell lung cancer

AI-based image analysis

VISIOPHARM®



More than an application...

Agilent Dako

PD-L1 APP, NSCLC is intended for use with digital images as an aid to in vitro diagnostic test for the detection and semi-quantitative measurement of Programmed death-ligand 1 (PD-L1) in tumor cells in formalin-fixed, paraffin-embedded neoplastic lung (FFPE) tissue.

It is indicated as an aid to the pathologist in the assessment of non-small cell lung cancer patients.

PD-L1 APP, NSCLC is your simple way to score PD-L1 by:

- Automatically identifying tissues and invasive tumors
- Detecting positive and negative tumor nuclei
- Delivering a tumor proportion score (TPS) and total tumor nuclei

Intended use	For in vitro diagnostic use (IVDR)
Indications included	Non-small cell lung cancer (NSCLC)
Scoring	Tumor proportion score (TPS)
Scanner compatibility	Hamamatsu NanoZoomer® S360 Slide Scanner MD Hamamatsu NanoZoomer® S60 Slide Scanner MD Philips IntelliSite Ultra Fast Scanner
Analysis	Tissue detection Invasive tumor detection Quantification Heatmap
Avaliable in	Europe

Agilent and Visiopharm — Advancing Digital Pathology

Agilent and Visiopharm are collaborating to advance digital pathology solutions based on a joint vision of end-to-end quality and standardization in tissue interpretation. Our partnership addresses the unmet needs of pathology labs around the world. Our shared goal is to provide specific technologies, products, and services to improve the standardization of pathology labs and accelerate accurate analyses. This effort will enable labs to gradually adopt digital technologies in a flexible and scalable manner.

Agilent

Trusted Answers

Not just an APP. Simple workflow, simple scoring.

The Visiopharm integrated workflow starts with the assessment of tissue and providing pathologists with objective interpretation support.

PD-L1 APP for NSCLC AI-based image analysis delivers accurate, consistent analysis assistance, improving lab standardization and enhancing your workflow (see Figure 1 viewing & confirmation).



Figure 1. PD-L1 APP NSCLC integrated and automated workflow.



Figure 2. The PD-L1 APP NSCLC analyzes the whole slide, automatically identifies sample and control tissue, detects nuclei in the invasive tumor, and calculates TPS along with a TPS heatmap.

The device provides a supplement to manual scoring and results must be confirmed by manual review by a qualified pathologist. Please refer to the User Guides for the applicable system used for viewing and reviewing purposes for further information on navigation and display of results.

Contact your local Agilent representative for more information about adopting the PD-L1 APP NSCLC and our other digital pathology solutions.

www.agilent.com

For in vitro diagnostic use.

D0042247_1.00

Published in the USA, December 1, 2023
29612 2023DEC01

Agilent
Trusted Answers